Drugs / SHR-1921
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05594875 | Dec 2022 → Apr 2024 | neoplasm | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06211023 | Feb 2024 → Jun 2026 | ovarian carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1921 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05594875 ↗ |